Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation

Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation

Saved in:

Bibliographic Details
Main Authors:	Kaibo Ding, Zhongsheng Peng, Yanjun Xu
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2025-03-01
Series:	Genes and Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352304224002058
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Inhibitory effect of 1,4,5,6-tetrahydroxy-7,8-diprenylxanthone against NSCLC with L858R/T790M/C797S mutant EGFR
by: Jing Wang, et al.
Published: (2024-11-01)

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
by: Brian J. Thomas, et al.
Published: (2024-11-01)

Efficacy of osimertinib in advanced T790M-positive NSCLC after progression to prior EGFR-TKI: real world data from a Brazilian cohort
by: Luiz Henrique Araujo, et al.
Published: (2020-01-01)

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
by: Ning Lou, et al.
Published: (2024-12-01)

Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report
by: Yoshihiro Go, et al.
Published: (2024-12-01)

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
by: Ying Wu, et al.
Published: (2024-04-01)

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2024-12-01)

The Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR-TKI-Resistant Mice
by: Jianfeng Sun, et al.
Published: (2024-01-01)

Identification of expression profiles and transcription factors during EGFR‐TKI acquired resistance in LUAD
by: Lili Feng, et al.
Published: (2024-12-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

EGFR T790M-Positive Lung Adenocarcinoma Metastases to the Pituitary Gland Causing Adrenal Insufficiency: A Case Report
by: Michael L. Adashek, et al.
Published: (2018-01-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations
by: Yueming He, et al.
Published: (2024-11-01)

Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments
by: Yen‐Shou Kuo, et al.
Published: (2025-09-01)

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer
by: Yuhong Ma, et al.
Published: (2024-12-01)

A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy
by: Jue Zhang, et al.
Published: (2025-01-01)

Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2
by: Shaoyi Cao, et al.
Published: (2024-12-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2025-01-01)

Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling
by: Jiahui Wu, et al.
Published: (2022-04-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling
by: Jiahui Wu, et al.
Published: (2024-12-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model
by: Bhaswati Sarcar, et al.
Published: (2019-10-01)

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024-12-01)

EGFR Amplification and Glioblastoma Stem-Like Cells
by: Katrin Liffers, et al.
Published: (2015-01-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil
by: Thais Abreu Almeida, et al.
Published: (2019-01-01)

A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR
by: Song Han, et al.
Published: (2025-01-01)

Gasdermin D regulates the activation of EGFR in colorectal cancer
by: Ying Li, et al.
Published: (2024-12-01)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
by: Álvaro Taus, et al.
Published: (2012-01-01)

Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
by: Sebastian Kraus
Published: (2024-10-01)

肝细胞癌及癌旁肝组织EGFR和EGFR vⅢ的表达及其临床意义
by: 徐立, et al.
Published: (2006-01-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma
by: Jeremy Slomka, et al.
Published: (2024-01-01)

Central nervous system metastases of lung adenocarcinoma harboring EGFR-activating mutations: survival results from a multidisciplinary approach, including EGFR-TKIs
by: Guilherme Harada, et al.
Published: (2020-01-01)

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
by: Hua-Jun Chen, et al.
Published: (2025-01-01)

Emerging targeted therapies in oral oncology: Focus on EGFR inhibition
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-09-01)